ALPINE IMMUNE SCIENCES, INC.
DelistedCIK 1626199fmd_1C14SAXQHPMVKWZ8243MERB752Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2013 to Mar 31, 2024, 42 periods
| Line item | FY2014 | FY2015 | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenues | – | 0 | 3 | 2 | 1 | 2 | 9 | 23 | 30 | 59 |
| Realized investment gains (losses) | – | – | – | – | – | – | – | 0 | 0 | 0 |
| Research and development | 12 | 0 | 3 | 11 | 29 | 36 | 27 | 59 | 70 | 81 |
| Total operating expenses | – | 1 | 4 | 17 | 39 | 45 | 38 | 73 | 88 | 103 |
| Operating income | (14) | (0) | (1) | (15) | (38) | (44) | (29) | (50) | (58) | (44) |
| Interest expense | 1 | – | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 0 |
| Interest and investment income | – | 0 | 0 | 1 | 1 | – | – | 0 | 3 | 12 |
| Other non-operating income (expense) | 0 | 0 | – | – | – | 1 | 1 | (0) | (0) | 0 |
| Income before taxes | – | (0) | (1) | (8) | (37) | (42) | (28) | (50) | (55) | (32) |
| Income tax expense | – | – | 0 | (0) | (0) | 0 | (0) | (0) | 2 | 0 |
| Net income from continuing operations | – | – | (1) | (8) | (36) | (42) | (28) | (50) | (58) | (32) |
| Net income | (15) | (0) | (1) | (8) | (36) | (42) | (28) | (50) | (58) | (32) |
| Net income to common shareholders | (15) | (23) | (31) | – | – | – | – | – | – | – |